The dipeptidyl peptidase-4 inhibitor alogliptin in combination with pioglitazone improves glycemic control, lipid profiles, and increases pancreatic insulin content in ob/ob mice

European Journal of Pharmacology

Volumn 602, Issue 2-3, 2009, Pages 448-454

  Moritoh, Yusuke ^a   Takeuchi, Koji ^a   Asakawa, Tomoko ^a   Kataoka, Osamu ^a   Odaka, Hiroyuki ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

Alogliptin; Dipeptidyl peptidase 4; Glucagon like peptide 1; ob ob mice; Pioglitazone; Type 2 diabetes mellitus

Indexed keywords

ADIPONECTIN; ALOGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLYCOSYLATED HEMOGLOBIN; INCRETIN; LIPID; PIOGLITAZONE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; FOOD INTAKE; GLUCAGON BLOOD LEVEL; GLYCEMIC CONTROL; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; ANTIGENS, CD26; BLOOD GLUCOSE; BODY WEIGHT; DRUG COMBINATIONS; EATING; ENZYME INHIBITORS; HORMONES; HYPERINSULINISM; INSULIN; LIPIDS; MALE; MICE; MICE, OBESE; PANCREAS; PIPERIDINES; THIAZOLIDINEDIONES; URACIL;

EID: 58149144587     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.11.017     Document Type: Article

References (50)

1. Ahren B. Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications. Diabetes Care 30 (2007) 1344-1350
2. Ahren B., Landin-Olsson M., Jansson P.A., Svensson M., Holmes D., and Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J. Clin. Endocrinol. Metab. 89 (2004) 2078-2084
3. Avramoglu R.K., Basciano H., and Adeli K. Lipid and lipoprotein dysregulation in insulin resistant states. Clin. Chim. Acta 368 (2006) 1-19
4. Baggio L.L., and Drucker D.J. Biology of incretins: GLP-1 and GIP. Gastroenterology 132 (2007) 2131-2157
5. Barnett A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int. J. Clin. Pract. 60 (2006) 1454-1470
6. Baron A.D., Schaeffer L., Shragg P., and Kolterman O.G. Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics. Diabetes 36 (1987) 274-283
7. Betteridge D.J. Effects of pioglitazone on lipid and lipoprotein metabolism. Diabetes Obes. Metab. 9 (2007) 640-647
8. Boden G., and Zhang M. Recent findings concerning thiazolidinediones in the treatment of diabetes. Expert Opin. Investig. Drugs 15 (2006) 243-250
9. Brown A.S. Lipid management in patients with diabetes mellitus. Am. J. Cardiol. 96 (2005) 26E-32E
10. Burkey B.F., Li X., Bolognese L., Russell M., Wang P.R., Villhauer E.B., and Hughes T.E. Combination treatment of a DPP-IV inhibitor NVP-LAF237 with pioglitazone completely normalized glucose tolerance in adult obese Zucker rats (abstract). Diabetes 51 (2002) 1383
11. Charpentier G. Oral combination therapy for type 2 diabetes. Diabetes Metab. Res. Rev. 18 Suppl 3 (2002) S70-76
12. Christopher R., Covington P., Davenport M., Fleck P., Mekki Q.A., Wann E.R., and Karim A. Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects. Clin. Ther. 30 (2008) 513-527
13. Covington P., Christopher R., Davenport M., Fleck P., Mekki Q.A., Wann E.R., and Karim A. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes. Clin. Ther. 30 (2008) 499-512
14. Deacon C.F. Circulation and degradation of GIP and GLP-1. Horm. Metab. Res. 36 (2004) 761-765
15. Defronzo R.A., Fleck P.R., Wilson C.A., and Mekki Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes mellitus and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes Care 31 (2008) 2315-2317
16. Diani A.R., Sawada G., Wyse B., Murray F.T., and Khan M. Pioglitazone preserves pancreatic islet structure and insulin secretory function in three murine models of type 2 diabetes. Am. J. Physiol., Endocrinol Metabol. 286 (2004) E116-122
17. Dormandy J.A., Charbonnel B., Eckland D.J., Erdmann E., Massi-Benedetti M., Moules I.K., Skene A.M., Tan M.H., Lefebvre P.J., Murray G.D., Standl E., Wilcox R.G., Wilhelmsen L., Betteridge J., Birkeland K., Golay A., Heine R.J., Koranyi L., Laakso M., Mokan M., Norkus A., Pirags V., Podar T., Scheen A., Scherbaum W., Schernthaner G., Schmitz O., Skrha J., Smith U., and Taton J. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (2005) 1279-1289
18. Drucker D.J. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action. Diabetes Care 30 (2007) 1335-1343
19. Drucker D.J., and Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368 (2006) 1696-1705
20. El-Ouaghlidi A., Rehring E., Holst J.J., Schweizer A., Foley J., Holmes D., and Nauck M.A. The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion. J. Clin. Endocrinol. Metab. 92 (2007) 4165-4171
21. Farilla L., Hui H., Bertolotto C., Kang E., Bulotta A., Di Mario U., and Perfetti R. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 143 (2002) 4397-4408
22. Feng J., Zhang Z., Wallace M.B., Stafford J.A., Kaldor S.W., Kassel D.B., Navre M., Shi L., Skene R.J., Asakawa T., Takeuchi K., Xu R., Webb D.R., and Gwaltney II S.L. Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J. Med. Chem. 50 (2007) 2297-2300
23. Garber A.J., Schweizer A., Baron M.A., Rochotte E., and Dejager S. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes. Metab. 9 (2007) 166-174
24. Gerstein H.C., Miller M.E., Byington R.P., Goff Jr. D.C., Bigger J.T., Buse J.B., Cushman W.C., Genuth S., Ismail-Beigi F., Grimm Jr. R.H., Probstfield J.L., Simons-Morton D.G., and Friedewald W.T. Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J. Med. 358 (2008) 2545-2559
25. Giorgino F., Laviola L., and Leonardini A. Pathophysiology of type 2 diabetes: rationale for different oral antidiabetic treatment strategies. Diabetes Res. Clin. Pract. 68 Suppl1 (2005) S22-S29
26. Harmon J.S., Gleason C.E., Tanaka Y., Poitout V., and Robertson R.P. Antecedent hyperglycemia, not hyperlipidemia, is associated with increased islet triacylglycerol content and decreased insulin gene mRNA level in Zucker diabetic fatty rats. Diabetes 50 (2001) 2481-2486
27. Herberg L., and Leiter E.H. Obesity/diabetes in mice with mutations in the leptin or leptin receptor genes. In: Shima A.A.F., and Shafrir E. (Eds). Animal Models of Diabetes a Primer (2001), Harwood academic publishers, Amsterdam 63-107
28. Holst J.J. On the physiology of GIP and GLP-1. Horm. Metab. Res. 36 (2004) 747-754
29. Jiang G., and Zhang B.B. Glucagon and regulation of glucose metabolism. Am. J. Physiol., Endocrinol Metabol. 284 (2003) E671-678
30. Jonas J.C., Sharma A., Hasenkamp W., Ilkova H., Patane G., Laybutt R., Bonner-Weir S., and Weir G.C. Chronic hyperglycemia triggers loss of pancreatic beta cell differentiation in an animal model of diabetes. J. Biol. Chem. 274 (1999) 14112-14121
31. Kjorholt C., Akerfeldt M.C., Biden T.J., and Laybutt D.R. Chronic hyperglycemia, independent of plasma lipid levels, is sufficient for the loss of beta-cell differentiation and secretory function in the db/db mouse model of diabetes. Diabetes 54 (2005) 2755-2763
32. Kubota N., Terauchi Y., Kubota T., Kumagai H., Itoh S., Satoh H., Yano W., Ogata H., Tokuyama K., Takamoto I., Mineyama T., Ishikawa M., Moroi M., Sugi K., Yamauchi T., Ueki K., Tobe K., Noda T., Nagai R., and Kadowaki T. Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways. J. Biol. Chem. 281 (2006) 8748-8755
33. Lambeir A.M., Durinx C., Scharpe S., and De Meester I. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit. Rev. Clin. Lab. Sci. 40 (2003) 209-294
34. Lee B., Shi L., Kassel D.B., Asakawa T., Takeuchi K., and Christopher R.J. Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys. Eur. J. Pharmacol. 589 (2008) 306-314
35. Madsbad S., Krarup T., Deacon C.F., and Holst J.J. Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials. Curr. Opin. Clin. Nutr. Metab. Care 11 (2008) 491-499
36. Meeuwisse-Pasterkamp S.H., van der Klauw M.M., and Wolffenbuttel B.H. Type 2 diabetes mellitus: prevention of macrovascular complications. Expert Rev. Cardiovasc. Ther. 6 (2008) 323-341
37. Moritoh Y., Takeuchi K., Asakawa T., Kataoka O., and Odaka H. Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice. Eur. J. Pharmacol. 588 (2008) 325-332
38. Nauck M.A., Meininger G., Sheng D., Terranella L., and Stein P.P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes. Metab. 9 (2007) 194-205
39. Patel A., MacMahon S., Chalmers J., Neal B., Billot L., Woodward M., Marre M., Cooper M., Glasziou P., Grobbee D., Hamet P., Harrap S., Heller S., Liu L., Mancia G., Mogensen C.E., Pan C., Poulter N., Rodgers A., Williams B., Bompoint S., de Galan B.E., Joshi R., and Travert F. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 358 (2008) 2560-2572
40. Perfetti R., and Hui H. The role of GLP-1 in the life and death of pancreatic beta cells. Horm. Metab. Res. 36 (2004) 804-810
41. Pfutzner A., Schneider C.A., and Forst T. Pioglitazone: an antidiabetic drug with cardiovascular therapeutic effects. Expert Rev. Cardiovasc. Ther. 4 (2006) 445-459
42. Pratley R., Reusch J., Fleck P., Wilson C., and Mekki Q. Efficacy and safety of alogliptin added to pioglitazone therapy in patients with type 2 diabetes. Diabetes 57 Suppl 1 (2008) A143 (Abstract)
43. Rolin B., Larsen M.O., Gotfredsen C.F., Deacon C.F., Carr R.D., Wilken M., and Knudsen L.B. The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. Am. J. Physiol., Endocrinol Metabol. 283 (2002) E745-E752
44. Rosenstock J., Brazg R., Andryuk P.J., Lu K., and Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin. Ther. 28 (2006) 1556-1568
45. Rosenstock J., Baron M.A., Camisasca R.P., Cressier F., Couturier A., and Dejager S. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes. Metab. 9 (2007) 175-185
46. Sloop K.W., Michael M.D., and Moyers J.S. Glucagon as a target for the treatment of type 2 diabetes. Expert Opin. Ther. Targets 9 (2005) 593-600
47. Takeuchi K., Moritoh Y., Asakawa T., Kataoka O., Zhang Z., and Odaka H. Effects of SYR-322, a novel inhibitor of dipeptidyl peptidase-IV alone or in combination with pioglitazone in obese and non-obese type 2 diabetes model rats and mice. Diabetes 55 Suppl 1 (2006) A465 (Abstract)
48. Turner R.C., Cull C.A., Frighi V., and Holman R.R. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 281 (1999) 2005-2012
49. Wajchenberg B.L. Beta-cell failure in diabetes and preservation by clinical treatment. Endocr. Rev. 28 (2007) 187-218
50. Wilding J. Thiazolidinediones, insulin resistance and obesity: finding a balance. Int. J. Clin. Pract. 60 (2006) 1272-1280